What is Trelegy Ellipta?
Trelegy Ellipta is a once-daily, triple-therapy inhaler used for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) [1]. It combines fluticasone furoate, umeclidinium, and vilanterol [1].
Who Makes Trelegy Ellipta?
Trelegy Ellipta is manufactured by GlaxoSmithKline (GSK) [1].
What are Trelegy Ellipta's Competitors?
Competitors to Trelegy Ellipta are other inhaled triple therapies for COPD, as well as dual-therapy inhalers [2, 3]. These include products that combine different classes of bronchodilators and inhaled corticosteroids (ICS).
Other Triple Therapy Inhalers for COPD
* Breo Ellipta (fluticasone furoate/vilanterol) [4]: While a dual therapy, it is in the same Ellipta device and from GSK, making it a related product.
* Anoro Ellipta (umeclidinium/vilanterol) [5]: Another dual therapy from GSK also using the Ellipta device.
* Symbicort (budesonide/formoterol) [6]: A dual ICS/long-acting beta2-agonist (LABA) therapy, often used as a foundational treatment before considering triple therapy.
* Advair Diskus/HFA (fluticasone propionate/salmeterol) [7]: A dual ICS/LABA.
* Dulera (mometasone furoate/formoterol) [8]: Another dual ICS/LABA.
* Stiolto Respimat (tiotropium/olodaterol) [9]: A dual long-acting muscarinic antagonist (LAMA)/LABA.
* Incrruse (umeclidinium) and Seebri BreezHaler (glycopyrronium): These are single-ingredient LAMA inhalers [10, 11]. While not triple therapies, they are components that can be combined with other inhalers to achieve triple therapy.
Combinations Achieving Triple Therapy
Physicians may prescribe a combination of two inhalers to achieve triple therapy, for example, a LAMA, a LABA, and an ICS [2, 3]. This approach provides an alternative route to triple therapy if a single inhaler product is not suitable or available.
How Does Trelegy Ellipta Work?
Trelegy Ellipta works by combining three active ingredients:
* Fluticasone furoate is an inhaled corticosteroid that reduces inflammation in the airways [1].
* Umeclidinium is a long-acting muscarinic antagonist (LAMA) that helps to relax and open the airways [1].
* Vilanterol is a long-acting beta2-agonist (LABA) that also helps to relax and open the airways [1].
Together, these components work to reduce exacerbations and improve lung function in COPD patients.
When Does Trelegy Ellipta's Patent Expire?
Patent expiry dates for combination drugs like Trelegy Ellipta can be complex due to patents covering individual ingredients, the combination, and the delivery device [12]. DrugPatentWatch.com tracks these patents and their expiry timelines, which are crucial for understanding when generic versions may become available [13]. Specific expiry dates for Trelegy Ellipta patents would be available on specialized patent tracking resources.
What are the Risks Associated with Trelegy Ellipta?
Common side effects of Trelegy Ellipta can include pneumonia, headache, and back pain [1]. Serious side effects may also occur [1]. Patients should discuss any concerns with their healthcare provider.